Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
PRME
#2265
Prime Medicine, Inc. Common Stock
4.6
2
+7.94%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+7.94%
Changement Mensuel
+6.21%
Evolution sur 6 mois
+35.48%
Changement Annuel
+87.04%
Clôture Précédente
4.2
8
Open
4.6
2
Bid
Ask
Low
4.6
2
High
4.6
2
Volume
111
Marchés
Actions des Marchés US
Soins de Santé
PRME
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
131.16 M
131.16 M
131.29 M
134.57 M
180.51 M
—
Valuation ratios
Enterprise value
389.62 M
200.51 M
169.4 M
278.59 M
928.63 M
1.58 B
Price to earnings ratio
-1.88
-1.77
-1.24
-1.58
-3.85
-8.44
Price to sales ratio
—
116.1
63.5
61.72
117.89
359.19
Price to cash flow ratio
-2.19
-2.82
-2.29
-3.15
-6.84
-15.09
Price to book ratio
0.54
2.26
0.36
0.58
1.48
4.68
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.16
0.14
0.16
0.19
0.13
0.62
Return on equity %
0.28
0.28
0.49
0.86
0.31
1.94
Return on invested capital %
191.8
154.15
151.97
121.05
—
—
Gross margin %
100
100
100
100
100
400
Operating margin %
25.95 K
2 025.74
3 603.3
4 787.17
4 405.96
14.82 K
EBITDA margin %
—
—
—
—
—
—
Net margin %
25.13 K
1 936.6
3 568.78
4 716.68
4 129.14
14.35 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
6.5
5.58
4.78
3.56
6.61
20.52
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0.01
0
0
0
0.02
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.22
-0.14
0.37
0.32
0.22
0.78
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
1.47
1.61
1.1
0.79
1.33
4.82
Net current asset value per share
2.05
1.79
1.25
0.94
1.44
5.42
Tangible book value per share
1.58
1.29
0.82
0.47
1.01
3.59
Working capital per share
1.74
1.47
0.99
0.67
1.22
4.35
Book value per share
1.58
1.29
0.82
0.47
1.01
3.59
Nouvelles
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates
Prime Drink Group schließt erste Tranche der Privatplatzierung ab
Prime Drink Group completes first closing of private placement
Prime: Maintaining "Buy" On Solidified Catalysts For Wilson's Disease And Beyond
Prime Drink Group plant Privatplatzierung von bis zu 5 Millionen Dollar
Prime Drink Group announces private placement to raise up to $5 million
Goldman Sachs bestätigt Rating für Prime Medicine nach Update zur Strategie bei Morbus Wilson
Goldman Sachs reiterates Early-Stage Biotech rating on Prime Medicine stock
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
Prime Medicine appoints Matthew Hawryluk as chief business officer
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
Prime Medicine Momentum Amid Pipeline Progress: Why I Choose To 'Hold' For Now (PRME)